Sunday, November 13, 2022 7:41:42 AM
I am confused. Is the self-imposed quite period in reference to the JA or because of the submission of data for review to the 4 regulators. NWBO has only 1 author/employee (Bosch) on the authors list. Other than that, the Doctors are sharing "New" trial results with the medical community.
The top Brass at NWBO have decided at the end of the PH3 to remain quite till approval and that time line is well beyond their control as we have experienced. The only communication is what the Regulatory Authority in the UK has told them to accomplish. Being able to provide the product (DCvax) to the medical community of the UK and PIP trial.
To me, dilution is keeping on the lights, required expansion, and new required study trials (PIP).
I really do not see how anyone can not think this product will not get approval this week or this coming year, it will happen, but it is in the hands or others at this point.
I am not her for the short term. I will be here till I lose it all or it will be a life changing event for my children and grand kids. If I lose it all, it will not change the rest of my life as I am a simple man.
The top Brass at NWBO have decided at the end of the PH3 to remain quite till approval and that time line is well beyond their control as we have experienced. The only communication is what the Regulatory Authority in the UK has told them to accomplish. Being able to provide the product (DCvax) to the medical community of the UK and PIP trial.
To me, dilution is keeping on the lights, required expansion, and new required study trials (PIP).
I really do not see how anyone can not think this product will not get approval this week or this coming year, it will happen, but it is in the hands or others at this point.
I am not her for the short term. I will be here till I lose it all or it will be a life changing event for my children and grand kids. If I lose it all, it will not change the rest of my life as I am a simple man.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
